# T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Transplantation

> **NCT05471661** · PHASE1,PHASE2 · COMPLETED · sponsor: **George Papanicolaou Hospital** · enrollment: 10 (actual)

## Conditions studied

- Opportunistic Fungal Infection
- Opportunistic Viral Infection
- Bone Marrow Transplant Infection

## Interventions

- **BIOLOGICAL:** Pentavalent-specific T cells (penta-STs)

## Key facts

- **NCT ID:** NCT05471661
- **Lead sponsor:** George Papanicolaou Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-22
- **Primary completion:** 2024-05-05
- **Final completion:** 2024-05-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05471661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05471661, "T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05471661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*